Financhill
Sell
28

AKRO Quote, Financials, Valuation and Earnings

Last price:
$39.89
Seasonality move :
15.51%
Day range:
$39.66 - $44.81
52-week range:
$17.86 - $58.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.23x
Volume:
1.3M
Avg. volume:
1.3M
1-year change:
91.59%
Market cap:
$3.2B
Revenue:
--
EPS (TTM):
-$3.75

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
AKRO
Akero Therapeutics
-- -$0.99 -- -16.23% $77.64
IART
Integra Lifesciences Holdings
$381.2M $0.43 -5.53% 241.78% $17.38
NBY
NovaBay Pharmaceuticals
$3M -$0.24 14.03% -95.43% $0.85
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
OGEN
Oragenics
-- -- -- -- $1.00
TOVX
Theriva Biologics
-- -$5.50 -- -8.25% $6.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
AKRO
Akero Therapeutics
$39.85 $77.64 $3.2B -- $0.00 0% --
IART
Integra Lifesciences Holdings
$12.25 $17.38 $952M 70.14x $0.00 0% 0.58x
NBY
NovaBay Pharmaceuticals
$0.56 $0.85 $3.3M -- $0.00 0% 0.15x
NNVC
Nanoviricides
$1.32 -- $20.6M -- $0.00 0% --
OGEN
Oragenics
$0.17 $1.00 $3.6M -- $0.00 0% 1.05x
TOVX
Theriva Biologics
$0.53 $6.00 $1.5M -- $0.00 0% 0.63x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
AKRO
Akero Therapeutics
-- 3.250 -- --
IART
Integra Lifesciences Holdings
54.74% 2.245 107.86% 0.57x
NBY
NovaBay Pharmaceuticals
4.54% -0.186 1.51% 0.75x
NNVC
Nanoviricides
-- 2.080 -- --
OGEN
Oragenics
-- 3.254 -- --
TOVX
Theriva Biologics
-- -2.512 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
AKRO
Akero Therapeutics
-- -$78M -- -- -- -$67.1M
IART
Integra Lifesciences Holdings
$194.4M -$15.5M -0.86% -1.88% -2.93% -$40.2M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
NNVC
Nanoviricides
-- -$2.1M -- -- -- -$2.2M
OGEN
Oragenics
-- -$3.4M -- -- -- -$2M
TOVX
Theriva Biologics
-- -$4.6M -- -- -- -$4.7M

Akero Therapeutics vs. Competitors

  • Which has Higher Returns AKRO or IART?

    Integra Lifesciences Holdings has a net margin of -- compared to Akero Therapeutics's net margin of -6.61%. Akero Therapeutics's return on equity of -- beat Integra Lifesciences Holdings's return on equity of -1.88%.

    Company Gross Margin Earnings Per Share Invested Capital
    AKRO
    Akero Therapeutics
    -- -$0.99 --
    IART
    Integra Lifesciences Holdings
    50.81% -$0.33 $3.4B
  • What do Analysts Say About AKRO or IART?

    Akero Therapeutics has a consensus price target of $77.64, signalling upside risk potential of 94.82%. On the other hand Integra Lifesciences Holdings has an analysts' consensus of $17.38 which suggests that it could grow by 41.84%. Given that Akero Therapeutics has higher upside potential than Integra Lifesciences Holdings, analysts believe Akero Therapeutics is more attractive than Integra Lifesciences Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    AKRO
    Akero Therapeutics
    9 0 0
    IART
    Integra Lifesciences Holdings
    2 5 2
  • Is AKRO or IART More Risky?

    Akero Therapeutics has a beta of -0.123, which suggesting that the stock is 112.286% less volatile than S&P 500. In comparison Integra Lifesciences Holdings has a beta of 1.268, suggesting its more volatile than the S&P 500 by 26.765%.

  • Which is a Better Dividend Stock AKRO or IART?

    Akero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra Lifesciences Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akero Therapeutics pays -- of its earnings as a dividend. Integra Lifesciences Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AKRO or IART?

    Akero Therapeutics quarterly revenues are --, which are smaller than Integra Lifesciences Holdings quarterly revenues of $382.7M. Akero Therapeutics's net income of -$70M is lower than Integra Lifesciences Holdings's net income of -$25.3M. Notably, Akero Therapeutics's price-to-earnings ratio is -- while Integra Lifesciences Holdings's PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akero Therapeutics is -- versus 0.58x for Integra Lifesciences Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AKRO
    Akero Therapeutics
    -- -- -- -$70M
    IART
    Integra Lifesciences Holdings
    0.58x 70.14x $382.7M -$25.3M
  • Which has Higher Returns AKRO or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to Akero Therapeutics's net margin of -49.65%. Akero Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    AKRO
    Akero Therapeutics
    -- -$0.99 --
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About AKRO or NBY?

    Akero Therapeutics has a consensus price target of $77.64, signalling upside risk potential of 94.82%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 50.71%. Given that Akero Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Akero Therapeutics is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    AKRO
    Akero Therapeutics
    9 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is AKRO or NBY More Risky?

    Akero Therapeutics has a beta of -0.123, which suggesting that the stock is 112.286% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

  • Which is a Better Dividend Stock AKRO or NBY?

    Akero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akero Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AKRO or NBY?

    Akero Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Akero Therapeutics's net income of -$70M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Akero Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akero Therapeutics is -- versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AKRO
    Akero Therapeutics
    -- -- -- -$70M
    NBY
    NovaBay Pharmaceuticals
    0.15x -- $2.4M -$1.2M
  • Which has Higher Returns AKRO or NNVC?

    Nanoviricides has a net margin of -- compared to Akero Therapeutics's net margin of --. Akero Therapeutics's return on equity of -- beat Nanoviricides's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    AKRO
    Akero Therapeutics
    -- -$0.99 --
    NNVC
    Nanoviricides
    -- -$0.14 --
  • What do Analysts Say About AKRO or NNVC?

    Akero Therapeutics has a consensus price target of $77.64, signalling upside risk potential of 94.82%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 392.42%. Given that Nanoviricides has higher upside potential than Akero Therapeutics, analysts believe Nanoviricides is more attractive than Akero Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    AKRO
    Akero Therapeutics
    9 0 0
    NNVC
    Nanoviricides
    0 0 0
  • Is AKRO or NNVC More Risky?

    Akero Therapeutics has a beta of -0.123, which suggesting that the stock is 112.286% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.32%.

  • Which is a Better Dividend Stock AKRO or NNVC?

    Akero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akero Therapeutics pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AKRO or NNVC?

    Akero Therapeutics quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. Akero Therapeutics's net income of -$70M is lower than Nanoviricides's net income of -$2M. Notably, Akero Therapeutics's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akero Therapeutics is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AKRO
    Akero Therapeutics
    -- -- -- -$70M
    NNVC
    Nanoviricides
    -- -- -- -$2M
  • Which has Higher Returns AKRO or OGEN?

    Oragenics has a net margin of -- compared to Akero Therapeutics's net margin of --. Akero Therapeutics's return on equity of -- beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    AKRO
    Akero Therapeutics
    -- -$0.99 --
    OGEN
    Oragenics
    -- -$0.27 --
  • What do Analysts Say About AKRO or OGEN?

    Akero Therapeutics has a consensus price target of $77.64, signalling upside risk potential of 94.82%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 493.12%. Given that Oragenics has higher upside potential than Akero Therapeutics, analysts believe Oragenics is more attractive than Akero Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    AKRO
    Akero Therapeutics
    9 0 0
    OGEN
    Oragenics
    0 1 0
  • Is AKRO or OGEN More Risky?

    Akero Therapeutics has a beta of -0.123, which suggesting that the stock is 112.286% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

  • Which is a Better Dividend Stock AKRO or OGEN?

    Akero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akero Therapeutics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AKRO or OGEN?

    Akero Therapeutics quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Akero Therapeutics's net income of -$70M is lower than Oragenics's net income of -$3.3M. Notably, Akero Therapeutics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akero Therapeutics is -- versus 1.05x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AKRO
    Akero Therapeutics
    -- -- -- -$70M
    OGEN
    Oragenics
    1.05x -- -- -$3.3M
  • Which has Higher Returns AKRO or TOVX?

    Theriva Biologics has a net margin of -- compared to Akero Therapeutics's net margin of --. Akero Therapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    AKRO
    Akero Therapeutics
    -- -$0.99 --
    TOVX
    Theriva Biologics
    -- -$1.60 --
  • What do Analysts Say About AKRO or TOVX?

    Akero Therapeutics has a consensus price target of $77.64, signalling upside risk potential of 94.82%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 1032.29%. Given that Theriva Biologics has higher upside potential than Akero Therapeutics, analysts believe Theriva Biologics is more attractive than Akero Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    AKRO
    Akero Therapeutics
    9 0 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is AKRO or TOVX More Risky?

    Akero Therapeutics has a beta of -0.123, which suggesting that the stock is 112.286% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

  • Which is a Better Dividend Stock AKRO or TOVX?

    Akero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akero Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AKRO or TOVX?

    Akero Therapeutics quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Akero Therapeutics's net income of -$70M is lower than Theriva Biologics's net income of -$4.4M. Notably, Akero Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akero Therapeutics is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AKRO
    Akero Therapeutics
    -- -- -- -$70M
    TOVX
    Theriva Biologics
    0.63x -- -- -$4.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

3 Recession-Proof ETFs to Invest in Now
3 Recession-Proof ETFs to Invest in Now

The U.S. gross domestic product (GDP) contracted 0.3% during the…

Is Butterfly Network the Best Small-Cap Stock?
Is Butterfly Network the Best Small-Cap Stock?

Brought to public trading by an SPAC merger in early…

Is Spotify a Millionaire-Maker Stock?
Is Spotify a Millionaire-Maker Stock?

Spotify (NYSE:SPOT) may seem like an expensive proposition trading closer…

Stock Ideas

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 40x

Alerts

Buy
60
RGC alert for May 10

Regencell Bioscience Holdings [RGC] is up 79.25% over the past day.

Buy
97
NGVC alert for May 10

Natural Grocers by Vitamin Cottage [NGVC] is up 30.26% over the past day.

Sell
38
ONTO alert for May 10

Onto Innovation [ONTO] is down 30.17% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock